InvestorsObserver
×
News Home

FSD Pharma Inc (HUGE) has gained 7.76% in a Week, Should You Buy?

Wednesday, November 22, 2023 12:23 PM | InvestorsObserver Analysts

Mentioned in this article

FSD Pharma Inc (HUGE) has gained 7.76% in a Week, Should You Buy?

A rating of 72 puts FSD Pharma Inc (HUGE) near the top of the Drug Manufacturers - Specialty & Generic industry according to InvestorsObserver. FSD Pharma Inc's score of 72 means it scores higher than 72% of stocks in the industry. FSD Pharma Inc also received an overall rating of 50, putting it above 50% of all stocks. Drug Manufacturers - Specialty & Generic is ranked 124 out of the 148 industries.

Overall Score - 50
HUGE has an Overall Score of 50. Find out what this means to you and get the rest of the rankings on HUGE!

What do These Ratings Mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. InvestorsObserver makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.
This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With FSD Pharma Inc Stock Today?

FSD Pharma Inc (HUGE) stock is trading at $1.25 as of 12:21 PM on Wednesday, Nov 22, a drop of -$0.10, or -7.41% from the previous closing price of $1.35. The stock has traded between $1.23 and $1.43 so far today. Volume today is high. So far 183,508 shares have traded compared to average volume of 99,742 shares. Click Here to get the full Stock Report for FSD Pharma Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App